Tag Archives: alter dna

Hidden magma pools pose eruption risks that we can’t yet detect

Volcanologists’ ability to estimate eruption risks is largely reliant on knowing where pools of magma are stored, deep in the Earth’s crust. But what happens if the magma can’t be spotted?

Hidden magma pools pose eruption risks that we can’t yet detect

Volcanologists’ ability to estimate eruption risks is largely reliant on knowing where pools of magma are stored, deep in the Earth’s crust. But what happens if the magma can’t be spotted?

Hidden magma pools pose eruption risks that we can’t yet detect

Volcanologists’ ability to estimate eruption risks is largely reliant on knowing where pools of magma are stored, deep in the Earth’s crust. But what happens if the magma can’t be spotted?

Hidden magma pools pose eruption risks that we can’t yet detect

Volcanologists’ ability to estimate eruption risks is largely reliant on knowing where pools of magma are stored, deep in the Earth’s crust. But what happens if the magma can’t be spotted?

Hidden magma pools pose eruption risks that we can’t yet detect

Volcanologists’ ability to estimate eruption risks is largely reliant on knowing where pools of magma are stored, deep in the Earth’s crust. But what happens if the magma can’t be spotted?

Hidden magma pools pose eruption risks that we can’t yet detect

Volcanologists’ ability to estimate eruption risks is largely reliant on knowing where pools of magma are stored, deep in the Earth’s crust. But what happens if the magma can’t be spotted?

Hidden magma pools pose eruption risks that we can’t yet detect

Volcanologists’ ability to estimate eruption risks is largely reliant on knowing where pools of magma are stored, deep in the Earth’s crust. But what happens if the magma can’t be spotted?

Hidden magma pools pose eruption risks that we can’t yet detect

Volcanologists’ ability to estimate eruption risks is largely reliant on knowing where pools of magma are stored, deep in the Earth’s crust. But what happens if the magma can’t be spotted?

FDA approves immunotherapy for first-line treatment of advanced gastric cancer

Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma.